Monoclonal antibodies (mAbs) were first described in the mid-1970s and there was great optimism around the clinical use of antibodies as “magic bullets” to target tumors. But this great hype gave way to pessimism as time went by. Antibodies derived from mouse induced unwanted immune responses in human subjects. Poor effector function in humans also limited murine Ab potency. Over the last 2-3 decades various technologies (display technologies, humanization, transgenic mice) have allowed the generation of Ab drugs that are better suited for the human immune system. As such, Antibody (Ab)-based therapeutics is at the center stage of drug discovery with antibodies being the fastest growing class of drugs. Antibodies are ideal for therapeutic interventions in part owing to their:
- High specificity
- High tolerance
- Long half-life that allows infrequent dosing
- Amenability to manipulation in order to improve binding and effector functions
Given some of these factors, there is a robust increase in the development of human mAbs. This interest is also fueled by advances in technologies to generate antibodies - transgenic mice, yeast display, phage display etc. As a result there has been a major shift in focus of many pharmaceutical companies as they move from exclusive small molecule drug discovery to a broader portfolio containing both, chemical entities [small molecules] as well as biotherapeutics [large molecules including antibodies].
The webpages in this technical resource section serve to provide a broad overview of the discovery process for generation of Ab-based therapeutics, while discussing basic concepts around Abs and their production. Discovery topics will include target selection, target assessment & validation, screening, lead identification and optimization, leading up to candidate selection. GenScript’s service capabilities in recombinant antibody (rAb) production are provided where necessary.
The next section in this series is “The History of Antibodies”. To review, click here.
GenScript Antibody Drug Discovery Services
- Antibody Discovery: GenScript’s Antibody Engineering group can build antibody library with up to 1010 individual clones, to speed up your antibody discovery efforts.
- Antibody Sequencing: GenScript’s advanced Antibody Sequencing technology offers fast and professional sequencing services for your monoclonal antibodies.
- Assays: GenScript has developed several cell-based immune-checkpoint functional assays to determine the immuno-modulatory profile of antibody leads.
- Antibody Engineering: GenScript scientists’ extensive experience in antibody engineering can provide superior services such as antibody humanization, affinity maturation and more.
- Antibody Production: With solid expertise in recombinant antibody (rAb) production techniques, GenScript provides a comprehensive rAb service portfolio that deliver microgram to gram quantities of pure rAb for each stage of your Ab drug discovery program.
- PK/PD Study: GenScript offers over 120 tumor and inflammation models for evaluation of in vivo efficacy, PK/PD, biomarker and bioanalysis studies. GenScript Anti-idiotype Antibody services are also a powerful tool for antibody drug PK/PD and immunogenicity studies.
Our customer service repsentatives are available 24 hours a day, Monday through Friday, to assist you.